Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
Type:
Grant
Filed:
September 4, 2015
Date of Patent:
April 4, 2017
Assignee:
SYNERGY PHARMACEUTICALS, INC.
Inventors:
Stephen Comiskey, Rong Feng, John Foss, Kunwar Shailubhai
Abstract: Disclosed are conjugates comprising the annexin 1-binding peptide IFLLWQR covalently linked to a therapeutic or detectable agent. Also disclosed are compositions comprising a moiety and a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are isolated nucleic acids comprising a nucleic acid sequence encoding a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are methods comprising administering to a subject a composition comprising a moiety and a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are methods of targeting a tumor cell in a subject comprising administering to the subject a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell.
Type:
Grant
Filed:
December 23, 2010
Date of Patent:
April 4, 2017
Assignees:
Burnham Institute for Medical Research, Hamamatsu University School of Medicine
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
March 28, 2017
Assignee:
SHIRE-NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
March 28, 2017
Assignee:
SHIRE-NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
March 28, 2017
Assignee:
SHIRE-NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
March 21, 2017
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Peptides (and derivatives thereof), topical compositions, and methods of diminishing signs of aging and/or improving health of human integuments are provided. The peptides are derived from human Growth Differentiation Factor 11 (GDF-11).
Type:
Grant
Filed:
June 17, 2015
Date of Patent:
March 21, 2017
Assignee:
Avon Products, Inc.
Inventors:
Jolanta Idkowiak-Baldys, John W. Lyga, Uma Santhanam
Abstract: Degradable bioprostheses made of collagen-based material having amine-based and ester-based crosslinks are provided, as are methods for their formation and use. Some embodiments of the present invention are directed towards a method of controlling the ratio of amine-based crosslinks to ester-based crosslinks within a collagen-based material to provide a tailorably crosslinked collagen-based material. Some embodiments provide a method of making a degradable bioprosthesis involving controlling crosslinking to afford a degradable bioprosthesis that is partially crosslinked. By controlling the ratio of amine-based to ester-based crosslinks, by controlling the level of crosslinking, or by controlling both of these features, degradable bioprostheses with tailored degradation rates can be synthesized. Some embodiments of degradable bioprostheses have degradation rates that are tailored to allow their use in particular medical applications.
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
March 14, 2017
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
March 14, 2017
Assignee:
SHIRE-NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
February 21, 2017
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: The present invention relates to a compound of the formula (I), (II), (III), (IV), (V), or (VI) or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection using the same.
Type:
Grant
Filed:
August 12, 2011
Date of Patent:
February 21, 2017
Assignee:
S&T GLOBAL, INC.
Inventors:
Zhuang Su, Zhengyu Long, Zhennian Huang, Suizhou Yang
Abstract: The invention provides compositions and methods for preventing or treating an ischemia-reperfusion injury, such as occurs during acute myocardial infarction and organ transplant in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide or a pharmaceutically acceptable salt thereof, and one or more additional active agents such as cyclosporine.
Abstract: A method of inhibiting protein kinases by administering polypeptides derived from alpha-neurotoxin, and inhibiting protein kinases. Diseases treated thereby include cancer, influenza, Tourette's syndrome, pain, and neurological deficits.
Type:
Grant
Filed:
December 28, 2015
Date of Patent:
January 31, 2017
Assignee:
Nuovo Biologics, LLC
Inventors:
Kent D. Miller, Billy S. Austin, Jay E. Yourist
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
January 31, 2017
Assignee:
NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Compositions and methods for delivering bioactive agents, such as vitamins, hormones, nutrients and drugs, by stabilizing and or solubilizing these agents in a polymer matrix. The carrier polymers can be used in drug delivery and are useful for delivery of small molecules. The carrier polymers also can be used in scaffolds for regenerative medicine.
Type:
Grant
Filed:
June 18, 2008
Date of Patent:
January 31, 2017
Assignee:
New York University
Inventors:
Jin Kim Montclare, Man Xia Lee, Jennifer Haghpanah
Abstract: The invention provides for the synthesis of more effective generators of a T-cell immune response by providing peptide derivatives that are MHC class I-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein the peptide derivative contains a non-natural amino acid substituted in place of a naturally-occurring amino acid residue at one or more primary anchor positions in the parent peptide or at position 6, position 7, or the C-terminus.
Type:
Grant
Filed:
August 6, 2015
Date of Patent:
January 24, 2017
Assignee:
Purdue Pharma L.P.
Inventors:
Donald J. Kyle, Daniel A. Soltis, Lynda G. Tussey
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
June 19, 2015
Date of Patent:
January 17, 2017
Assignee:
NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
January 17, 2017
Assignee:
NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
January 10, 2017
Assignee:
NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch